REGULATED PRESS RELEASE published on 10/07/2024 at 18:50, 1 month 15 days ago Disclosure of Share Capital and Voting Rights as of September 30, 2024 Edenred discloses share capital and voting rights as of September 30, 2024, in accordance with regulatory requirements. Details available on edenred.com under Investors/Shareholders section Edenred Share Capital Voting Rights Investors Regulatory Disclosure
BRIEF published on 09/17/2024 at 08:45, 2 months 6 days ago Edenred Announces Share Capital Decrease Through Treasury Shares Cancellation Edenred Share Capital Treasury Shares Buyback Program Cancellation
REGULATED PRESS RELEASE published on 09/17/2024 at 08:40, 2 months 6 days ago Share capital decrease by way of treasury shares cancellation Edenred SE reduces share capital by canceling treasury shares. 4,502,462 shares (1.80% of capital) repurchased and canceled. Company's total shares now 245,085,597 with par value €2 Share Capital Treasury Shares Repurchase Program Edenred SE Corporate Clients
BRIEF published on 09/13/2024 at 08:36, 2 months 10 days ago Edenred Announces New Share Buyback Mandate Edenred Share Buyback Investment Stock Market €300 Million
REGULATED PRESS RELEASE published on 09/13/2024 at 08:31, 2 months 10 days ago Share buyback mandate Edenred announces a new share buyback agreement with an investment services provider for an initial total maximum amount of €75 million, aiming to extend it until March 31, 2027 Edenred Share Buyback Agreement Investment Services Provider €75 Million
BRIEF published on 09/06/2024 at 11:59, 2 months 16 days ago EDENRED Discloses Share Capital and Voting Rights as of August 31, 2024 Edenred Share Capital Voting Rights Financial Disclosure August 2024
REGULATED PRESS RELEASE published on 09/06/2024 at 11:54, 2 months 16 days ago Disclosure of Share Capital and Voting Rights as of August 31, 2024 Edenred discloses share capital and voting rights as of August 31, 2024, in accordance with French regulations. Visit edenred.com for details Edenred Share Capital Voting Rights French Regulations Disclosure
BRIEF published on 08/05/2024 at 10:10, 3 months 17 days ago EDENRED Announces Share Capital and Voting Rights as of July 31, 2024 Edenred Share Capital Voting Rights Financial Disclosure July 2024
REGULATED PRESS RELEASE published on 08/05/2024 at 10:05, 3 months 17 days ago Disclosure of Share Capital and Voting Rights as of July 31, 2024 Edenred discloses share capital and voting rights according to French regulations. Details available on edenred.com under Investors/Shareholders section Edenred Share Capital Voting Rights Investors French Regulations
BRIEF published on 07/29/2024 at 18:38, 3 months 24 days ago Edenred successfully issues a €500 million bond Edenred Financial Structure Bond Issuance International Investors €500 Million
Published on 11/22/2024 at 23:55, 9 hours 25 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 50 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 15 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 50 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 15 hours 6 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 15 hours 27 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 25 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 20 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 2 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 14 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
